XML 56 R53.htm IDEA: XBRL DOCUMENT v2.4.0.6
Collaborative Arrangements (Details) (USD $)
 3 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 19 Months Ended
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2011
Sep. 30, 2011
Jun. 30, 2011
Mar. 31, 2011
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Sep. 30, 2012
Janssen Pharmaceutica, N.V.
Mar. 31, 2011
Janssen Pharmaceutica, N.V.
Dec. 31, 2012
Janssen Pharmaceutica, N.V.
Y
Dec. 31, 2011
Janssen Pharmaceutica, N.V.
Dec. 31, 2010
Janssen Pharmaceutica, N.V.
Dec. 31, 2006
Janssen Pharmaceutica, N.V.
Dec. 31, 2011
Mitsubishi Tanabe Pharma Corporation
Sep. 30, 2009
Mitsubishi Tanabe Pharma Corporation
Dec. 31, 2012
Mitsubishi Tanabe Pharma Corporation
Dec. 31, 2011
Mitsubishi Tanabe Pharma Corporation
Dec. 31, 2010
Mitsubishi Tanabe Pharma Corporation
Dec. 31, 2009
Mitsubishi Tanabe Pharma Corporation
D
Apr. 30, 2011
Cystic Fibrosis Foundation Therapeutics Incorporated
Y
Dec. 31, 2012
Cystic Fibrosis Foundation Therapeutics Incorporated
payment
Dec. 31, 2011
Cystic Fibrosis Foundation Therapeutics Incorporated
Dec. 31, 2010
Cystic Fibrosis Foundation Therapeutics Incorporated
Dec. 31, 2006
Cystic Fibrosis Foundation Therapeutics Incorporated
Jun. 30, 2011
Alios BioPharma, Inc
D
Y
Dec. 31, 2012
Alios BioPharma, Inc
lines
Dec. 31, 2011
Alios BioPharma, Inc
Dec. 31, 2012
Alios BioPharma, Inc
lines
Jun. 13, 2011
Alios BioPharma, Inc
Schedule of Collaborative Arrangements                                                                  
Drug development costs to be paid by collaborator (as a percent)                           50.00%     50.00%                                
Tiered royalty average range, as a percentage of net sales in the Janssen territories                           20.00%                                      
Up-front license payment                                 $ 165,000,000                                
Deferred revenue related to up-front license payment                           43,500,000                                      
Total contingent milestone payments earned                           350,000,000                                      
Milestone payment earned pursuant to the collaborative agreement                       200,000,000 50,000,000                                        
Notice period required to terminate without cause after receipt of marketing approval (in years)                           1                                      
Collaborative revenues recognized                                                                  
Royalty revenues 43,451,000 25,586,000 33,480,000 38,981,000 25,405,000 8,539,000 10,010,000 6,061,000 141,498,000 50,015,000 30,244,000     117,592,000 20,289,000 0                                  
Amortized portion of up-front payment                           12,428,000 12,428,000 12,428,000       12,744,000 38,232,000 38,232,000                      
Milestone revenues                           0 250,000,000 0       485,000 68,515,000 0               25,000,000   60,000,000  
Net reimbursement (payment) for telaprevir development costs                           (3,507,000) (8,418,000) 9,245,000                                  
Reimbursement for manufacturing services                           7,257,000 20,383,000 9,077,000       5,650,000 14,928,000 43,636,000                      
Collaborative revenues 9,234,000 6,919,000 11,552,000 24,381,000 81,176,000 231,066,000 29,879,000 67,601,000 52,086,000 409,722,000 113,126,000     16,178,000 274,393,000 30,750,000       18,879,000 121,675,000 81,868,000     17,000,000 13,700,000 0            
Total revenues 333,994,000 336,006,000 418,305,000 438,737,000 563,340,000 659,200,000 114,424,000 73,662,000 1,527,042,000 1,410,626,000 143,370,000     133,770,000 294,682,000 30,750,000                                  
License fee paid upon amendment of agreement                                     105,000,000                            
Milestone payment received                                   65,000,000                   1,500,000          
Notice period required to terminate without cause (in days)                                             60                    
Deferred revenue related to up-front license payment                           43,500,000                                      
Collaborative funding                                               75,000,000                  
Number of years over which funding will be made (in years)                                               5                  
Number of commercial milestone payments for achievement of certain sales levels for potentiator compound such as VX-770 (in payments)                                                 1                
Number of commercial milestone payments for achievement of certain sales levels for corrector compound such as VX-809 or VX-661 (in payments)                                                 2                
Up-front payment                                                                 60,000,000
Milestone payments                           0 250,000,000 0       485,000 68,515,000 0               25,000,000   60,000,000  
Development milestone payments, maximum                                                               312,500,000  
Commercial milestone payments, maximum                                                         750,000,000        
Notice period for termination of contract due to technical failure (in days)                                                         30        
Notice period for termination of contract after completion of clinical trials (in days)                                                         60        
Latest expiration period for royalty obligation after first commercial sale in country unless contract is terminated earlier (in years)                                                         10        
Intangible assets 663,500,000 [1]       663,500,000 [1]       663,500,000 [1] 663,500,000 [1]                                              
Noncontrolling Interest (Alios)                                                                  
Number of lines on balance sheet where noncontrolling interest is reported                                                           2   2  
Loss (income) before provision for (benefit from) income taxes                                                           20,044,000 9,536,000    
Decrease (increase) in fair value of contingent milestone and royalty payments                                                           (114,970,000) (69,950,000)    
Provision for (benefit from) income taxes (2,696,000) 21,355,000 20,063,000 32,000 22,660,000 (27,842,000) [2] 24,448,000 0 38,754,000 19,266,000 0                                     39,029,000 48,809,000    
Net loss (income) attributable to noncontrolling interest (Alios) (1,928,000) 31,076,000 30,463,000 (3,714,000) 29,512,000 7,342,000 (25,249,000) 0 55,897,000 11,605,000 0                                     (55,897,000) (11,605,000)    
Restricted cash and cash equivalents (Alios) 69,983,000 [1]       51,878,000 [1]       69,983,000 [1] 51,878,000 [1]                                       69,983,000 51,878,000 69,983,000  
Prepaid expenses and other current assets 24,673,000 [1]       14,889,000 [1]       24,673,000 [1] 14,889,000 [1]                                       672,000 2,299,000 672,000  
Property and equipment, net 433,609,000 [1]       133,176,000 [1]       433,609,000 [1] 133,176,000 [1]                                       1,728,000 1,925,000 1,728,000  
Intangible assets, excluding goodwill                                                           250,600,000 250,600,000 250,600,000  
Goodwill 30,992,000 [1]       30,992,000 [1]       30,992,000 [1] 30,992,000 [1]                                       4,890,000 4,890,000 4,890,000  
Other assets 9,668,000 [1]       11,268,000 [1]       9,668,000 [1] 11,268,000 [1]                                       861,000 133,000 861,000  
Accounts payable 101,292,000 [1]       74,642,000 [1]       101,292,000 [1] 74,642,000 [1]                                       1,054,000 4,132,000 1,054,000  
Accrued expenses 264,884,000 [1]       243,187,000 [1]       264,884,000 [1] 243,187,000 [1]                                       6,099,000 4,304,000 6,099,000  
Income taxes payable (Alios) 715,000 [1]       12,075,000 [1]       715,000 [1] 12,075,000 [1]                                       715,000 12,075,000 715,000  
Deferred tax liability 280,367,000 [1]       243,707,000 [1]       280,367,000 [1] 243,707,000 [1]                                       152,781,000 116,121,000 152,781,000  
Other liabilities, excluding current portion 13,902,000 [1]       7,287,000 [1]       13,902,000 [1] 7,287,000 [1]                                       910,000 1,030,000 910,000  
Redeemable noncontrolling interest (Alios) 38,530,000 [1]       37,036,000 [1]       38,530,000 [1] 37,036,000 [1]                                       38,530,000 37,036,000 38,530,000  
Noncontrolling interest (Alios) 196,672,000 [1]       141,633,000 [1]       196,672,000 [1] 141,633,000 [1]                                       196,672,000 141,633,000 196,672,000  
Collaborative revenues 9,234,000 6,919,000 11,552,000 24,381,000 81,176,000 231,066,000 29,879,000 67,601,000 52,086,000 409,722,000 113,126,000     16,178,000 274,393,000 30,750,000       18,879,000 121,675,000 81,868,000     17,000,000 13,700,000 0            
Research and development expense associated with collaborative programs                 $ 133,000,000 $ 146,000,000 $ 156,000,000                                            
[1] Amounts include the assets and liabilities of Vertex’s variable interest entity (“VIE”), Alios BioPharma, Inc. (“Alios”). Vertex’s interests and obligations with respect to the VIE’s assets and liabilities are limited to those accorded to Vertex in its agreement with Alios. See Note B, "Collaborative Arrangements," to these consolidated financial statements for amounts.
[2] During the third quarter of 2011, the Company recorded an impairment charge of $105.8 million. In connection with this impairment charge, the Company recorded a benefit from income taxes of $32.7 million resulting in a net decrease in net income attributable to Vertex related to this impairment charge of $73.1 million in the third quarter of 2011.